{"disease":{"id":"urothelial-cancer","name":"Urothelial Cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":17},"drugs":{"marketed":[{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (BCG-unresponsive)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (platinum-ineligible)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (MIBC, neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (platinum-ineligible)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (MIBC, neoadjuvant)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer (BCG-unresponsive)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"Urothelial Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06167356","title":"Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03955913","title":"A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations","phase":"","overall_status":"COMPLETED","enrollment_count":3679,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07386847","title":"A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT03036098","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03682068","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1246,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06469229","title":"Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04314245","title":"Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":1170,"lead_sponsor_name":"AnchorDx Medical Co., Ltd.","has_results":false},{"nct_id":"NCT02516241","title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1126,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06026189","title":"Safely Reduce Cystoscopic Evaluations for Hematuria Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT04923178","title":"A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07396038","title":"INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Necmettin Erbakan University","has_results":false},{"nct_id":"NCT04970472","title":"Bio Clinical Collection of Urothelial Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04223856","title":"Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":886,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04527991","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT02603432","title":"A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05092958","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":654,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07129993","title":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":630,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03390504","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":629,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT03474107","title":"A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02983045","title":"A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Nektar Therapeutics","has_results":true},{"nct_id":"NCT02256436","title":"A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":542,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04535921","title":"Fear of Cancer Recurrence in Genitourinary Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false},{"nct_id":"NCT04718948","title":"Multimodal Spectroscopy to Detect Urothelial Cancer in Urine","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT02379429","title":"Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07097142","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03775265","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07106762","title":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05080998","title":"Longitudinal Bladder Cancer Study for Tumour Recurrence","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Pacific Edge Limited","has_results":false},{"nct_id":"NCT06967961","title":"Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02052778","title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT07259226","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05945108","title":"Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05810623","title":"Single-Dose Intravesical Chemotherapy After Diagnostic URS","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":394,"lead_sponsor_name":"David D'Andrea","has_results":false},{"nct_id":"NCT02335424","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06982690","title":"Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":370,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06380062","title":"Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT03288545","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":348,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}